Joseph Hodges, MD
Radiation Oncology · Longview, TXNPI 1144554577
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 90.1% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 15.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $805, more than ten times the $28 reported in 2019.
Across 74 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$294
- AstraZeneca$200
- Zimmer Biomet$123
- Novartis$109
- Daiichi Sankyo Inc.$102
- Novocure Inc.$101
- plus $931 from 25 others
Across 5 payments — averaging $790.40 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$4K
What the payments were for
- Food & beverage$1,67590%
- Education$18410%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 7 | $294 |
| AstraZeneca | 10 | $200 |
| Zimmer Biomet | 1 | $123 |
| Novartis | 6 | $109 |
| Daiichi Sankyo Inc. | 4 | $102 |
| Novocure Inc. | 6 | $101 |
| Siemens Medical Solutions USA, Inc. | 1 | $99 |
| Merck | 5 | $97 |
| AbbVie | 3 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $58 |
| Pfizer | 2 | $48 |
| Incyte Corporation | 2 | $43 |
| Visionrt, Inc. | 1 | $39 |
| Eisai Inc. | 2 | $38 |
| Blueprint Medicines Corporation | 2 | $37 |
| Jazz Pharmaceuticals Inc. | 2 | $35 |
| Teleflex LLC | 1 | $33 |
| Blue Earth Diagnostics | 2 | $32 |
| Sanofi | 1 | $25 |
| Sobi, Inc | 1 | $24 |
| Mirati Therapeutics, Inc. | 1 | $24 |
| Bayer | 1 | $22 |
| Boston Scientific | 1 | $21 |
| Seagen Inc. | 1 | $19 |
| Taiho Oncology, Inc. | 1 | $19 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $17 |
| Caris MPI, Inc. | 1 | $15 |
| Exelixis Inc. | 1 | $14 |
| AVEO Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accelero-None$123
How this compares
$1,859 in reported general payments places this provider in the 70th percentile of 418 radiation oncology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $1,910 |
| Tamsulosin Hcl | 163 | $1,436 |
| Triamcinolone Acetonide | 46 | $750 |
| SsdSilver Sulfadiazine | 11 | $291 |
| Methylprednisolone | 13 | $85 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Longview
- Bernard TaylorLongview$28K
- James WelshHouston$421K
- Stephen ChunHouston$344K
- Jim HsiangCorpus Christi$258K
- Chad TangHouston$183K
- Phuoc TranHouston$177K
- Hak ChoyDallas$119K
- Steven LinHouston$105K
- Benjamin SchrankHouston$100K
- Robert TimmermanDallas$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.